These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 4301399)

  • 1. [Prerequisites for neurovirological and neurotoxicological tests in animal experiment].
    Glees P
    Dtsch Med Wochenschr; 1968 Dec; 93(49):2383-6 passim. PubMed ID: 4301399
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurovirulence.
    Wood D
    Dev Biol Stand; 1999; 101():127-9. PubMed ID: 10566785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the mutagenic action of proflavine on type 3 poliovirus.
    Pervikov YV; Vorohsilova MK; Chumakov MP; Savinov AP; Yurovetskaya AL
    Acta Virol; 1973 Jul; 17(4):365. PubMed ID: 4148222
    [No Abstract]   [Full Text] [Related]  

  • 4. Morphometric method for evaluating the neurovirulence of live poliomyelitis vaccine.
    Tyufanov AV; Stefanov SB
    Bull World Health Organ; 1979; 57(5):815-7. PubMed ID: 232013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Studies on safety tests of inactivated poliomyelitis vaccines. IV. Comparative safety tests in rhesus monkeys and long-tailed monkeys (Cercopithecus aethiops)].
    Günther O; Hövel H; von Mettenheim A; Burde K; Heber L; Unterharnscheidt F
    Zentralbl Bakteriol Orig; 1966 Jun; 200(2):137-50. PubMed ID: 4296870
    [No Abstract]   [Full Text] [Related]  

  • 6. [Studies on safety tests of inactivated poliomyelitis vaccines. V. Pathomorphological changes in the CNS of rhesus monkeys (Macaca rhesus) and long-tailed monkeys (Cercopithecus aethiops) following intracerebral and intralumbar inoculation with inactivated poliovirus types I, II, and 3].
    Unterharnscheidt F; Günther O; Hövel H; Burde K; Heber L
    Zentralbl Bakteriol Orig; 1966 Jun; 200(2):150-66. PubMed ID: 4296871
    [No Abstract]   [Full Text] [Related]  

  • 7. On some problems of complications in the central nervous system due to vaccination.
    Egashira Y
    Jpn J Med Sci Biol; 1968 Aug; 21(4):297-8. PubMed ID: 4303420
    [No Abstract]   [Full Text] [Related]  

  • 8. A collaborative study of the histopathological evaluation of the WHO neurovirulence test for poliovirus vaccines.
    Wood DJ; Heath AB; Marsden SA
    Biologicals; 1994 Mar; 22(1):45-51. PubMed ID: 8068313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies on safety tests of inactivated poliomyelitis vaccines. VI. On the effect of cortisone in monkey experiments].
    Günther O; Unterharnscheidt F; Hövel H
    Zentralbl Bakteriol Orig; 1966 Jun; 200(2):166-79. PubMed ID: 4967641
    [No Abstract]   [Full Text] [Related]  

  • 10. Inactivated vaccines based on alternatives to wild-type seed virus.
    Chumakov K; Dragunsky E; Ivshina A; Enterline J; Wells V; Nomura T; Gromeier M; Wimmer E
    Dev Biol (Basel); 2001; 105():171-7. PubMed ID: 11763325
    [No Abstract]   [Full Text] [Related]  

  • 11. Tissue culture of viruses (author's transl).
    Can J Med Technol; 1974 Jun; 36(3):231 passim. PubMed ID: 4368290
    [No Abstract]   [Full Text] [Related]  

  • 12. Pathogenesis of viral infections of the nervous system.
    Johnson RT; Mims CA
    N Engl J Med; 1968 Jan; 278(1):23-30 contd. PubMed ID: 4295224
    [No Abstract]   [Full Text] [Related]  

  • 13. Investigation of some possibilities of producing type 3 vaccine poliovirus with greater genetic stability. I. Preliminary experiments with passage variants.
    Elbert LB; Chumakov MP; Krutyanskaya GL; Ralph NM; Tyufanov AV
    Acta Virol; 1968 May; 12(3):193-202. PubMed ID: 4385148
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies on the characteristics of poliovirus type 3. II. Characteristics of "hot" clones.
    Jarzabek Z; Sadowski W; Kańtoch M; Magrath D; Krawczyński K
    Acta Virol; 1976 Oct; 20(5):366-72. PubMed ID: 63237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative monkey neurovirulence of Sabin type III poliovirus vaccines.
    Boulger LR; Marsden SA; Magrath DI; Taffs LF; Schild GC
    J Biol Stand; 1979 Apr; 7(2):97-111. PubMed ID: 225329
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of new approaches to poliovirus vaccine neurovirulence tests.
    Wood DJ
    Dev Biol Stand; 1996; 86():79-83. PubMed ID: 8785995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for a rubella virus vaccine.
    Parkman PD; Meyer HM
    Prog Med Virol; 1969; 11():80-106. PubMed ID: 4984711
    [No Abstract]   [Full Text] [Related]  

  • 18. Murine neurovirulence studies with a chimeric poliovirus: in vivo generation of a mutant base-paired stable attenuated poliovirus.
    Lee C; Young C
    Microb Pathog; 1998 Oct; 25(4):215-25. PubMed ID: 9817825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits, risks and costs of viral vaccines.
    Koplan JP; Axnick NW
    Prog Med Virol; 1982; 28():180-91. PubMed ID: 6806868
    [No Abstract]   [Full Text] [Related]  

  • 20. [Problems in producing some antiviral preparations].
    Grachev VP; Mironova LL; Drozdov SG; Avdeeva LI; Popova VD
    Vestn Akad Med Nauk SSSR; 1977; (5):11-7. PubMed ID: 407738
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.